Dynavax Technologies (NASDAQ:DVAX) and Albertsons Companies have partnered to provide HEPLISAV-B at latter’s more than 1,700 pharmacies nationwide, with a special focus on people living with diabetes.
Through this partnership, patients will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month.
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Shares are up 4% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.